よむ、つかう、まなぶ。
【参考１】診療の手引き・第9.0版 (22 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00416.html |
| 出典情報 | 「新型コロナウイルス感染症に係る予防接種の実施に関する手引き」の改訂について（2／10付 事務連絡）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
●新型コロナウイルス感染症（COVID-19） 診療の手引き・第 9.0 版 ●２ 臨床像
・Menni C, et al. Symptom prevalence，duration，and risk of hospital admission in individuals infected with SARSCoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE
COVID Study. Lancet 2022.
・Prendki V, et al. Caring for older adults during the COVID-19 pandemic. Clin Microbiol Infect 2022.
・Pulliam JRC, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South
Africa. Science 2022.
・Sakurai A, et al. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med 2020.
・Sigal A, et al. Estimating disease severity of Omicron and delta SARS-CoV-2 infections. Nat Rev Immunol 2022.
・UK Office for National Statistics. Comparing the risk of death involving coronavirus (COVID-19) by variant, England:
December 2021. 22 Feb 2022.
・WHO. COVID-19 Clinical management: Living guideline.13 Jan 2023.
・Whitaker M, et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat
Commun 2022.
・Wu Z, et al. Characteristics of and important lessons from the coronavirus disease 2019（COVID-19）outbreak in
China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA
2020.
2. 重症化のリスク因子
・国立感染症研究所．新型コロナワクチンの有効性を検討した症例対照研究の暫定報告（第３報）2022.
・ COVIREGI-JP/REBIND 登録患者におけるオミクロン株症例重症化リスク因子の検討（第 83 回新型コロナウイルス感染症
対策アドバイザリーボード資料）
・US CDC. Science Brief: Evidence used to update the list of underlying medical conditions associated with higher
risk for severe COVID-19. 15 June 2022.
・Danza P, et al. SARS-CoV-2 infection and hospitalization among adults aged ≥18 years，by vaccination status，
before and during SARS-CoV-2 B.1.1.529 (Omicron) variant predominance — Los Angeles County，California，
November 7， 2021–January 8，2022. MMWR 2022.
・Malik P, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ
Evid Based Med 2021.
・Peckham H, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU
admission. Nat Commun 2020.
・Sugiyama M, et al. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and
severe/critical disease in patients with COVID-19. Gene 2021．
・Terada M, et al. Risk factors for severity on
admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in
Japan. BMJ Open 2021.
・Yek C, et al. Risk factors for severe COVID-19 outcomes among persons aged >18 years who completed a
primary COVID-19 vaccination series – 465 health care facilities，United States，December 2020-October 2021
MMWR 2022.
・Zhang Q, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020.
3. 胸部画像所見
・Kwee TC, et al. Chest CT in COVID-19: what the radiologist needs to know. Radiographics 2020.
・Kanne JP, et al. COVID-19 imaging: what we know now and what remains unknown. Radiology 2021.
4. 合併症
・国立感染症研究所．予防接種法に基づき医療機関等から予防接種後副反応疑い報告として届けられた新型コロナワクチン接
種後の心筋炎関連事象の特徴．2022.2.18.
・Gupta A, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020.
・Hoenigl M, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries.
Lancet Microbe 2022.
・Horiuchi H, et al. COVID-19-related thrombosis in Japan: Final report of a questionnaire-based survey in 2020.
J Atheroscler Thromb 2021.
・Koehler P, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM
consensus criteria for research and clinical guidance. Lancet Infect Dis 2021.
・Lansbury L, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020.
・Made CI, et al. Presence of genetic variants among young men with severe COVID-19. JAMA 2020.
・Nishimoto Y, et al. The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in
Japan: from the CLOT-COVID study. J Cardiol 2022.
・Oxley TJ, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 2020.
・Patel A, et al. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis，India. Emerg
Infect Dis 2021．
・Prattes J, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019
patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol
Infect 2021.
・Salim SH, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ
2020.
22
・Menni C, et al. Symptom prevalence，duration，and risk of hospital admission in individuals infected with SARSCoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE
COVID Study. Lancet 2022.
・Prendki V, et al. Caring for older adults during the COVID-19 pandemic. Clin Microbiol Infect 2022.
・Pulliam JRC, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South
Africa. Science 2022.
・Sakurai A, et al. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med 2020.
・Sigal A, et al. Estimating disease severity of Omicron and delta SARS-CoV-2 infections. Nat Rev Immunol 2022.
・UK Office for National Statistics. Comparing the risk of death involving coronavirus (COVID-19) by variant, England:
December 2021. 22 Feb 2022.
・WHO. COVID-19 Clinical management: Living guideline.13 Jan 2023.
・Whitaker M, et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat
Commun 2022.
・Wu Z, et al. Characteristics of and important lessons from the coronavirus disease 2019（COVID-19）outbreak in
China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA
2020.
2. 重症化のリスク因子
・国立感染症研究所．新型コロナワクチンの有効性を検討した症例対照研究の暫定報告（第３報）2022.
・ COVIREGI-JP/REBIND 登録患者におけるオミクロン株症例重症化リスク因子の検討（第 83 回新型コロナウイルス感染症
対策アドバイザリーボード資料）
・US CDC. Science Brief: Evidence used to update the list of underlying medical conditions associated with higher
risk for severe COVID-19. 15 June 2022.
・Danza P, et al. SARS-CoV-2 infection and hospitalization among adults aged ≥18 years，by vaccination status，
before and during SARS-CoV-2 B.1.1.529 (Omicron) variant predominance — Los Angeles County，California，
November 7， 2021–January 8，2022. MMWR 2022.
・Malik P, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ
Evid Based Med 2021.
・Peckham H, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU
admission. Nat Commun 2020.
・Sugiyama M, et al. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and
severe/critical disease in patients with COVID-19. Gene 2021．
・Terada M, et al. Risk factors for severity on
admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in
Japan. BMJ Open 2021.
・Yek C, et al. Risk factors for severe COVID-19 outcomes among persons aged >18 years who completed a
primary COVID-19 vaccination series – 465 health care facilities，United States，December 2020-October 2021
MMWR 2022.
・Zhang Q, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020.
3. 胸部画像所見
・Kwee TC, et al. Chest CT in COVID-19: what the radiologist needs to know. Radiographics 2020.
・Kanne JP, et al. COVID-19 imaging: what we know now and what remains unknown. Radiology 2021.
4. 合併症
・国立感染症研究所．予防接種法に基づき医療機関等から予防接種後副反応疑い報告として届けられた新型コロナワクチン接
種後の心筋炎関連事象の特徴．2022.2.18.
・Gupta A, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020.
・Hoenigl M, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries.
Lancet Microbe 2022.
・Horiuchi H, et al. COVID-19-related thrombosis in Japan: Final report of a questionnaire-based survey in 2020.
J Atheroscler Thromb 2021.
・Koehler P, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM
consensus criteria for research and clinical guidance. Lancet Infect Dis 2021.
・Lansbury L, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020.
・Made CI, et al. Presence of genetic variants among young men with severe COVID-19. JAMA 2020.
・Nishimoto Y, et al. The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in
Japan: from the CLOT-COVID study. J Cardiol 2022.
・Oxley TJ, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 2020.
・Patel A, et al. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis，India. Emerg
Infect Dis 2021．
・Prattes J, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019
patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol
Infect 2021.
・Salim SH, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ
2020.
22